Found 2 articles
Meihua International Medical Technologies Co., Ltd. Announces Pricing of $36,000,000 Initial Public Offering
Meihua International Medical Technologies Co., Ltd. today announced the pricing of its initial public offering (the "Offering") of 3,600,000 ordinary shares at a public offering price of $10.00 per ordinary share.
Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients
Centanafadine, an investigational compound for the treatment of ADHD, demonstrated statistically significant improvements vs. placebo for primary and key secondary efficacy endpoints in both studies In the combined analysis of tolerability across the two studies, no adverse event was reported by more than 7 percent of patients An estimated 5 percent (11 million) adults in the U.S. are diagnosed with ADHD 1 TOKYO &